Stockreport

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ALX Oncology Holdings Inc.  (ALXO) 
PDF - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following stro [Read more]